These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11157 related articles for article (PubMed ID: 16507218)

  • 1. Integrins: molecular targets in cancer therapy.
    Tucker GC
    Curr Oncol Rep; 2006 Mar; 8(2):96-103. PubMed ID: 16507218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
    Reardon DA; Nabors LB; Stupp R; Mikkelsen T
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
    Scaringi C; Minniti G; Caporello P; Enrici RM
    Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
    Reardon DA; Neyns B; Weller M; Tonn JC; Nabors LB; Stupp R
    Future Oncol; 2011 Mar; 7(3):339-54. PubMed ID: 21417900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strides in melanoma announced: maximizing value comes next.
    Tuma RS
    J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
    [No Abstract]   [Full Text] [Related]  

  • 7. Small molecule integrin antagonists in cancer therapy.
    Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
    Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances and perspectives in the treatment of advanced melanoma.
    Livingstone E; Zimmer L; Vaubel J; Schadendorf D
    J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targeted therapies in melanoma.
    Kudchadkar RR; Gonzalez R; Lewis K
    Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New molecular target therapy for thyroid neoplasms and malignant melanomas].
    Okano S
    Nihon Jibiinkoka Gakkai Kaiho; 2015 Nov; 118(11):1366-7. PubMed ID: 26891495
    [No Abstract]   [Full Text] [Related]  

  • 12. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 13. Highlights from the ASCO annual meeting.
    Printz C
    Cancer; 2013 Sep; 119(17):3104-5. PubMed ID: 24037669
    [No Abstract]   [Full Text] [Related]  

  • 14. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin inhibitors reaching the clinic.
    Stupp R; Ruegg C
    J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrins as A New Target for Cancer Treatment.
    Łasiñska I; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(5):580-586. PubMed ID: 30451118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
    Cai W; Chen X
    Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrins as therapeutic targets.
    Goodman SL; Picard M
    Trends Pharmacol Sci; 2012 Jul; 33(7):405-12. PubMed ID: 22633092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
    Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
    Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 558.